To date, 200 people from around the world have signed the Third Global Congress Global Congress Declaration on Fundamental Public Interest Principles for International Intellectual Property Negotiations. The Declaration, drafted at the recent Global Congress in Cape Town, South Africa,…
Two events this week will examine issues in international intellectual property. September 11, The Promise and the Peril of Intellectual Property Licensing for Indigenous Assets. September 12, The Marrekesh Treaty to Facilitate Access to Published Works for Persons Who Are Blind, Visually…
Health groups rally in Delhi as protests spread across the developing world. [Posted on the Don’t Trade Our Lives Away blog, 10 April, 2013, New Delhi] Thousands of people living with HIV, cancer patient groups & public health activists rallied on…
We have been informed about the repeated attempt of the EU to include Intellectual Property Rights provisions that are very likely to undermine the stable supply of affordable life-saving medicines to poorer parts of the world. It is extremely worrisome that, despite assurance made by the Indian government regarding its determination not to include any measures hampering the production and provision of affordable generic medicines, the EU continues to put pressure on the Indian counterpart to accept Data Exclusivity, Intellectual Property Enforcement Measures and Investment Rules, all of which are designed to protect the interests of European pharmaceutical giants by curbing the availability of generic medicines cheaply produced in India. It is apparent that these provisions aim to secure bigger profits for large European pharmaceutical corporations and discourage production of cheap generic medicines in India, which have been saving millions of lives across the world.
Dear H.E. Dr. Manmohan Singh, We, the undersigned organizations from Thailand, are writing this letter to express our grave concern over the Indian Government’s shift in their position on the EU-India bilateral free trade agreement (FTA), which is to compromise…
[Delhi Network of Positive People] With the goal concluding the agreement by early April fast approaching, negotiations have now reached an intense phase with regular meetings to fast track its conclusion. The Indian Prime Minister has reportedly asked the Indian…
Trade officials from the EU and India are meeting today to continue negotiations of a free trade agreement, which they hope to complete by the end of the year. The European Union is seeking to include TRIPS-Plus patent and data…
AUTHOR: Brook Baker. ABSTRACT: European Customs officials have used fictive patent rights to justify the seizure of lawful generic medicines produced in India and destined for non-European markets. Following a public outcry and initiation of two WTO complaints, the EU…
UNAIDS Executive Director Michel Sidibe has warned against the inclusion of TRIPS-Plus provisions in the EU-India Free Trade Agreement that would jeopardize the continued manufacture and export of generic medicines. India currently produces the majority of antiretrovirals used in the…
Speaking at an Indian Parliamentary committee meeting on IPRs, Minster of Commerce and Industry Shri Anand Sharma spoke out against seizures of generic medicines in the Netherlands. “These detentions of Indian generics by Europe were deemed to be TRIPS violative…
On March 2, the Asia Pacific Network of Positive People, the Indian Drug Users Network, the Delhi Network of Positive People, and the Cancer Patients AIDS Association will be joined by UN Special Rapporteur on the Right to Health Anand…
CIS-India has posted the current IPR chapter of the EU-India FTA. The text shows the positions of Indian and EU negotiators on each provision, and it shows that India is rejecting TRIPS-Plus Enforcement provisions related to border measures for goods…